Smooth sailing so far for AbbVie's GT1 HCV combo

Share this article:
AbbVie released the first Phase III results from its SAPPHIRE-1 study, which is investigating its multi-drug hepatitis C combo with ribavirin in genotype 1 patients. Patients who had not yet received therapy saw an SVR12 rate of 96%. GT-1 is the most prolific type of HCV worldwide. The company confirmed that it is on track for “major regulatory submissions” in the second quarter of 2014.

Gilead's candidate sofosbuvir—which is slated to receive an approval decision Dec. 8—recently received an FDA advisory panel's full support for use in GT-1 infection, along with interferon and ribavirin.

Merck, too, has a dog in the fight. Its protease inhibitors MK-5172 and MK-8472 are currently undergoing testing in Phase II trials for GT-1. ISI Group analyst Mark Schoenebaum noted earlier this month that the drug may be only 18 months behind Gilead in the race for the first all-oral treatment for GT1.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.